Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine (Nasdaq: EDIT) reported new preclinical data for its in vivo gene-editing candidate EDIT-401 presented at the 94th European Atherosclerosis Society Congress.
A single dose in non-human primates produced ~≥90% mean reductions in LDL-C, Lp(a), and ApoB, with rapid, dose-dependent effects and highly correlated changes linked to LDLR upregulation.
Editas is running GLP toxicology studies, reporting EDIT-401 was well-tolerated at 1.5 mg/kg, and received positive FDA pre-IND feedback. The company plans an Australian CTN by mid-2026 and aims for early in vivo human proof-of-concept data by end-2026.
Editas Medicine (Nasdaq: EDIT) reported new preclinical data for EDIT-401, its in vivo CRISPR candidate for hyperlipidemia, at the 2026 ASGCT and TIDES meetings. A single dose in non-human primates produced ≥90% mean LDL-C reduction with ≥6-fold hepatic LDLR increase and maintained LDL-C lowering for ~6 months across 1.5–3.0 mg/kg.
According to the company, EDIT-401 showed a promising preclinical safety profile at 1.5 mg/kg, hepatocyte-targeted delivery with undetectable oocyte delivery, and dose-dependent LDL-C reduction. Mouse data with EDIT-401(mu) suggest dose adjustments may not be needed for HeFH patients. DNA-LLM models also supported broader in vivo upregulation applications.
Editas Medicine (Nasdaq: EDIT) reported Q1 2026 results and business updates on May 5, 2026. Key highlights: EDIT-401 showed >90% mean LDL-C reduction in preclinical studies and remains on track for a first-in-human study later in 2026 with early proof-of-concept data by year-end. Cash was $123.6M as of March 31, 2026, with runway into Q3 2027. Q1 net loss was $25.0M ($0.26/share); R&D expense was $17.6M and G&A was $10.2M. The USPTO reaffirmed a PTAB decision in favor of the Broad Institute on March 26, 2026.
Editas Medicine (Nasdaq: EDIT) announced five accepted abstracts presenting new preclinical data for EDIT-401, its lead in vivo CRISPR development candidate for hyperlipidemia, at ASGCT, TIDES USA, and EAS in May 2026. Presentations include oral and poster sessions reporting LDLR upregulation and LDL-C lowering in animal models.
Abstracts will be available on conference sites and presentations posted on the company website during the meetings.
Editas Medicine (Nasdaq: EDIT) said the U.S. Patent and Trademark Office has reaffirmed the PTAB’s decision favoring the Broad Institute on inventorship in the CRISPR/Cas9 interference, marking the third PTAB ruling finding Broad first to invent CRISPR/Cas9 in eukaryotic (including human) cells.
Editas holds exclusive licenses to the CRISPR/Cas9 patents at issue and says its broader CRISPR/Cas9 and CRISPR/Cas12a intellectual property portfolio across multiple jurisdictions remains intact; CVC retains the right to appeal to the CAFC.
Editas Medicine (Nasdaq: EDIT) reported Q4 and full-year 2025 results and business updates on March 9, 2026. Key highlights: EDIT-401 showed >90% mean LDL-C reduction in preclinical non-human primates and remains on track for an IND/CTA submission by mid-2026 and first-in-human dosing later in 2026. Cash and cash equivalents were $146.6M as of Dec 31, 2025, with a projected runway into Q3 2027. Full-year net loss was $160.1M (EPS -$1.80). The company expects early human proof-of-concept data by year-end 2026 and topline dose-finding results in 2027.
Editas Medicine (Nasdaq: EDIT) announced management will participate in two investor conferences in March 2026: TD Cowen 46th Annual Health Care Conference and Barclays 28th Annual Global Healthcare Conference. Both appearances are fireside chats; dates, times, and locations are listed. Live webcasts and archived replays will be available via the company’s Investors website for approximately 30 days after each event.
Investors can view the March 2, 10:30 a.m. ET session in Boston and the March 12, 8:00 a.m. ET session in Miami Beach via the company’s investor webcasts.
Editas Medicine (Nasdaq: EDIT) reported third quarter 2025 results and business updates on Nov 10, 2025. Key highlights include preclinical data showing ≥90% LDL-C reduction in non-human primates within 48 hours after a single dose of EDIT-401, durable LDL-C lowering in mice, and a mean ≥6-fold increase in liver LDLR protein. The company remains on track to submit an IND/CTA for EDIT-401 by mid-2026 and target initial human proof-of-concept by year-end 2026. Financially, cash and marketable securities were $165.6M as of Sept 30, 2025, cash runway extended into Q3 2027, Q3 net loss was $25.1M, and Q3 collaboration revenue rose to $7.5M.
Editas Medicine (Nasdaq: EDIT) announced a moderated digital poster presentation at the American Heart Association Scientific Sessions 2025 in New Orleans, Nov 7–10, 2025. The poster, titled “A transformative LDL cholesterol–lowering in vivo CRISPR gene editing medicine that functionally upregulates LDLR in mice and non-human primates”, is scheduled for Saturday, November 8, 10:45 a.m.–11:45 a.m. CT in the Basic Science Zone during the session Cutting-Edge Gene and Precision Therapies. Presenter: Anshul Gupta, Vice President, Preclinical Development. Final abstract number is 4364195. The accepted abstract is available on the AHA website and a copy of the poster will be posted in the company’s Posters & Presentations web section at the time of the presentation and remain accessible afterwards.
Editas Medicine (NASDAQ: EDIT) reported in vivo preclinical proof-of-concept data for EDIT-401 on October 9, 2025, showing robust LDL-cholesterol lowering in animal models.
Key readouts: ≥90% mean LDL-C reduction in non-human primates within 48 hours and in mice with high baseline LDL-C; a ≥6-fold mean increase in LDLR protein in NHP liver; LDL-C reductions were durable in a three-month mouse study. Data were presented at the ESGCT 32nd Annual Congress and will be posted on the company website.